USA • New York Stock Exchange • NYSE:ARE • US0152711091
The current stock price of ARE is 55.9 USD. In the past month the price increased by 4.94%. In the past year, price decreased by -41.75%.
ChartMill assigns a technical rating of 3 / 10 to ARE. When comparing the yearly performance of all stocks, ARE is a bad performer in the overall market: 84.54% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ARE. ARE may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ARE reported a non-GAAP Earnings per Share(EPS) of 0.07. The EPS decreased by -96.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.22% | ||
| ROE | -9.3% | ||
| Debt/Equity | 0.76 |
19 analysts have analysed ARE and the average price target is 66.74 USD. This implies a price increase of 19.39% is expected in the next year compared to the current price of 55.9.
For the next year, analysts expect an EPS growth of -263.52% and a revenue growth -10.34% for ARE
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| WELL | WELLTOWER INC | 68.08 | 134.466B | ||
| VTR | VENTAS INC | 132.44 | 38.776B | ||
| OHI | OMEGA HEALTHCARE INVESTORS | 23.51 | 13.382B | ||
| DOC | HEALTHPEAK PROPERTIES INC | 63.82 | 11.71B | ||
| AHR | AMERICAN HEALTHCARE REIT INC | 66.69 | 9.143B | ||
| CTRE | CARETRUST REIT INC | 24.54 | 8.673B | ||
| HR | HEALTHCARE REALTY TRUST INC | N/A | 5.95B | ||
| SBRA | SABRA HEALTH CARE REIT INC | 24.73 | 4.745B | ||
| DHCNL | DIVERSIFIED HEALTHCARE T - DHC 6 1/4 02/01/46 | N/A | 4.443B |
View all stocks in the Health Care REITs Industry | View all stocks in the Real Estate Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Alexandria Real Estate Equities, Inc. engages in the provision of space for lease. The company is headquartered in Pasadena, California and currently employs 514 full-time employees. The firm is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. The company has a Labspace asset base predominantly concentrated in markets with barriers to entry.
ALEXANDRIA REAL ESTATE EQUIT
26 North Euclid Avenue
Pasadena CALIFORNIA 91101 US
CEO: Stephen A. Richardson
Employees: 514
Phone: 16265780777
Alexandria Real Estate Equities, Inc. engages in the provision of space for lease. The company is headquartered in Pasadena, California and currently employs 514 full-time employees. The firm is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. The company has a Labspace asset base predominantly concentrated in markets with barriers to entry.
The current stock price of ARE is 55.9 USD. The price increased by 1.38% in the last trading session.
ALEXANDRIA REAL ESTATE EQUIT (ARE) has a dividend yield of 5.22%. The yearly dividend amount is currently 5.32.
ARE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
ARE stock is listed on the New York Stock Exchange exchange.
19 analysts have analysed ARE and the average price target is 66.74 USD. This implies a price increase of 19.39% is expected in the next year compared to the current price of 55.9.
The outstanding short interest for ALEXANDRIA REAL ESTATE EQUIT (ARE) is 5.47% of its float.